

Acute lymphocytic leukemia (ALL) - Pipeline Insight, 2020

<https://marketpublishers.com/r/A362752ABEDDEN.html>

Date: October 2020

Pages: 180

Price: US\$ 3,500.00 (Single User License)

ID: A362752ABEDDEN

Abstracts

This report can be delivered to the clients within 72 - 96 Hours

DelveInsight's, "Acute Lymphocytic Leukemia – Pipeline Insight, 2020," report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in Acute Lymphocytic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Acute Lymphocytic Leukemia Understanding

Acute Lymphocytic Leukemia: Overview

Acute lymphocytic leukemia (ALL) is also called acute lymphoblastic leukemia. "Acute" means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. 'Lymphocytic' means it develops from early (immature) forms of lymphocytes, a type of white blood cell.

ALL starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made). Most often, the leukemia cells invade the blood fairly quickly. They can also sometimes spread to other parts of the body, including the lymph nodes, liver,

spleen, central nervous system (brain and spinal cord), and testicles (in males). Some cancers can also start in these organs and then spread to the bone marrow, but these cancers are not leukemia.

Symptoms

The early signs and symptoms of ALL may be like the flu or other common diseases. Some of the common signs and symptoms are:

Weakness or feeling tired.

Fever or drenching night sweats.

Easy bruising or bleeding.

Petechiae (flat, pinpoint spots under the skin, caused by bleeding).

Shortness of breath.

Weight loss or loss of appetite.

Pain in the bones or stomach.

Pain or feeling of fullness below the ribs.

Painless lumps in the neck, underarm, stomach, or groin.

Having many infections.

Diagnosis

The following tests and procedures may be used:

Physical exam and health history: An exam of the body to check general signs of health, including checking for signs of disease, such as infection or anything else that seems unusual. A history of the patient's health habits and past illnesses and treatments will also be taken.

Complete blood count (CBC) with differential: A procedure in which a sample of blood is drawn and checked for the following:

The number of red blood cells and platelets.

The number and type of white blood cells.

The amount of hemoglobin (the protein that carries oxygen) in the red blood cells.

The portion of the blood sample made up of red blood cells.

Bone marrow aspiration and biopsy: The removal of bone marrow, blood, and a small piece of bone by inserting a hollow needle into the hipbone or breastbone. A pathologist views the bone marrow, blood, and bone under a microscope to look for abnormal cells.

Treatment

Four types of standard treatment are used for Acute Lymphocytic Leukemia:

Chemotherapy: It is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Radiation therapy: Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing

Chemotherapy with stem cell transplant: Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells

Targeted therapy: Targeted therapy is a type of treatment that uses drugs or other substances to attack cancer cells. Targeted therapy may cause less harm to normal cells than chemotherapy or radiation therapy do.

Acute Lymphocytic Leukemia Emerging Drugs Chapters

This segment of the Acute Lymphocytic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Lymphocytic Leukemia Emerging Drugs

CPX-351: Jazz Pharmaceuticals

Vyxeos (cytarabine and daunorubicin) liposome for injection, or CPX-351, is an investigational product being evaluated for the treatment of AML and is a combination of cytarabine and daunorubicin encapsulated within a nano-scale liposome at a 5:1 molar ratio. It is currently in phase II stage of development for ALL.

JZP-458: Jazz Pharmaceuticals

JZP-458 is being developed by Jazz Pharmaceuticals for the treatment of Acute Lymphoblastic Leukemia. It is currently in phase II/III stage of development.

UCART22: Cellectis

UCART22 is one of Cellectis' wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Like CD19, CD22 is a cell surface antigen expressed from the pre-B-cell stage of development through mature B-cells. CD22 expression occurs in more than 90% of patients with B-ALL. It is currently in phase I stage of development.

JZP-341: Jazz Pharmaceuticals

JZP-341 is being developed by Jazz Pharmaceuticals for the treatment of Acute Lymphoblastic Leukemia. It is currently in preclinical stage of development.

Further product details are provided in the report.

Acute Lymphocytic Leukemia: Therapeutic Assessment

This segment of the report provides insights about the different Acute Lymphocytic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Lymphocytic Leukemia

There are approx. 250+ key companies which are developing the therapies for Acute Lymphocytic Leukemia. The companies which have their Acute Lymphocytic Leukemia drug candidates in the most advanced stage, i.e. phase II/III include Jazz Pharmaceuticals and others

Phases

DelveInsight's report covers around 250+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Acute Lymphocytic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravenous

Oral

Parenteral

Subcutaneous.

Molecule Type

Products have been categorized under various Molecule types such as

Gene therapies

Small molecule

Vaccines

Polymers

Peptides

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Lymphocytic Leukemia: Pipeline Development Activities

Acute lymphocytic leukemia (ALL) - Pipeline Insight, 2020

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acute Lymphocytic Leukemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Lymphocytic Leukemia drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Lymphocytic Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve Acute Lymphocytic Leukemia.

In July 2016, Jazz Pharmaceuticals and Pfenex announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates.

In June 2018, Cellectis stated that the US Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application to initiate a phase I clinical trial for UCART22

Acute Lymphocytic Leukemia Report Insights

Acute Lymphocytic Leukemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Acute Lymphocytic Leukemia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Acute Lymphocytic Leukemia drugs?

How many Acute Lymphocytic Leukemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Lymphocytic Leukemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Lymphocytic Leukemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Acute Lymphocytic Leukemia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

PersonGen BioTherapeutics

Novartis Pharmaceuticals

Jazz Pharmaceuticals

Takara Bio Inc.

Cellectis S.A.

AbbVie

Autolus Limited

Juventas Cell Therapy Ltd.

Pinze Lifetechnology Co. Ltd.

Celgene

Key Products

CD7 CAR-T cells infusion

CTL019

JZP-458

TBI-1501

UCART22

Navitoclax

AUTO1

CNCT19

PZ01 CAR-T cells

JCAR017

Contents

Introduction

Executive Summary

Acute Lymphocytic Leukemia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Acute Lymphocytic Leukemia – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Acute Lymphocytic Leukemia companies' collaborations, Licensing, Acquisition -Deal Value Trends

Acute Lymphocytic Leukemia Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III and Phase II/III)

Comparative Analysis

JZP-458: Jazz Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

CPX-351: Jazz Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis

UCART22: Cellectis

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

- Comparative Analysis

JZP-341: Jazz Pharmaceuticals

- Product Description

- Research and Development

- Product Development Activities

Inactive Products

- Comparative Analysis

Acute Lymphocytic Leukemia Key Companies

Acute Lymphocytic Leukemia Key Products

Acute Lymphocytic Leukemia- Unmet Needs

Acute Lymphocytic Leukemia- Market Drivers and Barriers

Acute Lymphocytic Leukemia- Future Perspectives and Conclusion

Acute Lymphocytic Leukemia Analyst Views

Acute Lymphocytic Leukemia Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Acute Lymphocytic Leukemia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Acute Lymphocytic Leukemia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Acute lymphocytic leukemia (ALL) - Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/A362752ABEDDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A362752ABEDDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970